Research suggests off-label prescribing of medications is common
A study evaluating off-label prescribing of medications in a primary care network in Canada suggests the practice is common, although it varies by medication, patient and physician characteristics, according to a report published Online First by Archives of Internal Medicine. The report is part of the journal's Health Care Reform series.
Off-label prescribing is the practice of using prescription medications for indications that have not received regulatory approval. The practice is suspected to be a factor of preventable adverse medication events, the authors write in their study background.
Tewodros Eguale, M.D., M.Sc., of McGill University, Montreal, Canada, and colleagues used the Medical Office of the XXI Century primary care electronic health record network research program in Quebec to examine off-label use. A total of 113 primary care physicians wrote 253,347 electronic prescriptions for 50,823 patients from January 2005 through December 2009.
Overall, 11 percent of medications were prescribed for an off-label indication and 79 percent of off-label use lacked strong scientific evidence, the results indicate. The authors note the magnitude of off-label use was less than in a U.S. study.
In the present study, the highest proportion of off-label prescribing involved central nervous system medications (26.3 percent), anti-infective agents (17.1 percent) and ear-nose-throat medications (15.2 percent), according to the study results.
The results indicate that medications with three or four approved indications were associated with lower off-label use compared to those with one or two approved indications. Medications approved after 1995 also were associated with lower off-label use than those approved before 1981. Physicians with high scores on evidence-based practice were less likely to prescribe off-label.
"In conclusion, our findings indicate that off-label prescribing is common in primary care and varies by drug class, the number of approved indications for the drug, the age of the drug, patients' sex and physicians' attitude toward evidence-based medicine," the authors conclude. "Electronic health records can be used to document treatment indication at the time of prescribing and may pave the way for enhanced postmarketing evaluation of drugs if linked to treatment outcomes."
In an editorial, Patrick G. O'Malley, M.D., M.P.H., of the Uniformed Services University of the Health Sciences, Bethesda, Md., writes: "The principles and goals of labeling are worthy in that they seek to systematically identify the benefits and harms associated with drugs in order to allow the public to optimize the trade-off between drug risk and harm. However, there is substantial room to grow in realizing these ideals in practice."
"The reality is that when faced with difficult symptom syndromes that are unresponsive to available treatments, clinicians resort to trying what seems reasonable in order to alleviate suffering," O'Malley continues.
"Here is my view about a way forward on this topic. First, the discourse needs to focus less on overuse or underuse or off-label use and more on evolving toward better measurement of use, better assessment of appropriate use based on linkage to clinical outcomes and better processes to optimize use," he concludes.
More information: Arch Intern Med. Published online April 16, 2012. doi:10.1001/archinternmed.2012.340
Arch Intern Med. Published online April 9, 2012. doi:10.1001/archinternmed.2012.789
Journal reference:
JAMA Internal Medicine
Provided by
JAMA and Archives Journals
-
Off-label use: Oft not evidence based
Aug 21, 2009 |
not rated yet |
0
-
Stanford researcher criticizes FDA plans to reduce oversight of off-label drug use
Apr 03, 2008 |
not rated yet |
0
-
Doctors should disclose off-label prescribing to their patients
Nov 11, 2008 |
not rated yet |
0
-
Researchers: Strengthen restrictions on off-label promotion by pharmaceutical companies
Oct 28, 2008 |
not rated yet |
0
-
Atypical antipsychotics may aid symptons for some off-label uses, but not others
Sep 27, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Driving and hands-free talking lead to spike in errors, study shows
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
Pollen count apps for smartphones are nothing to sneeze at
Kate O'Reilly's spring allergy survival kit includes the usual stuff - nasal sprays, allergy pills and a box of tissues. This season, she's added a new weapon to her line of defense: an app on her smartphone.